Status:

COMPLETED

Clinical Study to Test a New Drug to Treat Major Depression

Lead Sponsor:

GlaxoSmithKline

Conditions:

Depressive Disorder, Major

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

Brief Summary

In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in ...

Eligibility Criteria

Inclusion

  • Key
  • Adult subjects with primary diagnosis of moderate to severe MDD without psychotic features, for at least 4 weeks and one previous MDD episode
  • Males or Females who agree to use protocol specified contraception if of child bearing potential
  • BMI 18.5-35.0 kg/m2
  • Normal liver function tests
  • Key

Exclusion

  • History of liver disease or positive hepatitis B surface antigen or hepatitis C antibody in the last 3 months
  • Elevated liver function tests on \>2 ocassions in the last 7 months
  • Significant medical illness, autoimmune disease or infectious disease
  • Pregnant or nursing females
  • Excessive and regular alcohol consumption
  • History of substance abuse or dependence in past 6 months or positive urine drug screen
  • Significant suicidal or homicidal risk
  • Currently receiving chronic biological or pharmacologic anti-inflammatory therapy or is not euthyroid
  • Psychoactive drugs within 1 week or 5 half lives of randomization visit
  • Treatment resistant subjects

Key Trial Info

Start Date :

September 25 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 7 2010

Estimated Enrollment :

128 Patients enrolled

Trial Details

Trial ID

NCT00976560

Start Date

September 25 2009

End Date

July 7 2010

Last Update

November 14 2017

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

GSK Investigational Site

Hoffman Estates, Illinois, United States, 60169

2

GSK Investigational Site

Park Ridge, Illinois, United States, 60068

3

GSK Investigational Site

New York, New York, United States, 10128

4

GSK Investigational Site

Columbus, Ohio, United States, 43210